Date: 2017-01-12
Type of information: Collaboration agreement
Compound:
Company: Merck KGaA (Germany) Palantir Technologies (USA - CA)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 12, 2017, Merck KGaA announced a partnership with Palantir Technologies, developer of the world’s most sophisticated data integration and analysis software. The partnership will leverage Palantir’s advanced data analytics capabilities to help Merck KGaAbetter and more rapidly develop and deliver medicines to patients, commercialize new products, and improve patient outcomes. Initially Merck KGaA will apply Palantir’s technology to cancer treatment and patient services. Ultimately Merck KGaA plans to deploy Palantir’s technology across all three of the company’s business sectors Healthcare, Life Science and Performance Materials.
The partnership will launch with three initiatives within the Healthcare business sector of Merck KGaA.
• Medical Research & Drug Development: The partnership will increase precision of the drug development process by developing a collaborative data and analytics platform so that Merck KGaA researchers can analyze real-world and bioinformatics data to understand the patients who may benefit most.
• Global Patient Intimacy: The partnership will improve the experience of patients using Merck KGaA products by utilizing large-scale data sources to increase adherence and understand real-world drug efficacy.
• Global Supply Chain: Merck KGaA and Palantir’s data and analytics platform will improve supply chain forecasting and agility in order to provide medicines to patients around the world with maximum speed and reliability.
Biomedical research generates unprecedented volumes of rapidly evolving data every day. But accessing, learning from, and expanding on those assets has become a huge bottleneck in scientists’ ability to bring new innovations from the bench to the bedside. Through their combined expertise, Merck KGaA and Palantir will aim to harness the power locked inside that data for the benefit of patients.
Financial terms: Financial details were not disclosed.
Latest news:
